Discover groundbreaking technologies and bold ideas redefining the future of sight
March 9-11, 2026 - Orlando, Florida
Discover groundbreaking technologies and bold ideas redefining the future of sight
March 9-11, 2026 - Orlando, Florida
SWITCH: Vision Innovation Summit by EssilorLuxottica is where the future of vision care takes center stage.
Scheduled for March 9–11, 2026 in Orlando, immediately before Vision Expo, this three-day event will spark meaningful conversation around everything from AI wearables to med-tech to myopia innovation, capturing the true potential beyond frames and lenses to shape the future of vision care.
A Forum for the Future
SWITCH: Vision Innovation Summit is more than an event—it is a platform for bold ideas and breakthrough discoveries. SWITCH is your opportunity to engage in forward-thinking dialogue and discover innovations that will redefine patient care in a connected world.
Experience Innovation Firsthand
Attendees will have exclusive access to EssilorLuxottica’s most powerful innovations:
- Lens technologies such as Transitions®, Varilux®, and Crizal® and the first and only FDA-market authorized spectacle lens to slow the progression of myopia in children¹²
- Smart eyewear and medtech including Ray-Ban Meta, Oakley Meta, and Nuance Audio Glasses
- Cutting-edge diagnostic technologies from Heidelberg, Espansione, and Cellview
Inspire. Imagine. Innovate.
Designed to spark dialogue and fuel transformation, SWITCH extends the journey from inspiration to action. This is where the industry’s future is not only unveiled—it’s shaped.
Join us in Orlando, March 9–11, 2026, and be part of the conversation redefining what’s possible in vision care..
Turn your Essilor Preferred Rewards program points into an unforgettable experience. Redeem a package to attend this brand-new industry event! .
INFORMATION REQUEST
To receive more information about SWITCH: Vision Innovation Summit by EssilorLuxottica, and to request an invitation, please complete the following form.
1. Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
2. Essilor International, data on file (2025).